Primary care physicians' knowledge and attitudes regarding prescription opioid abuse and diversion

Clinical Journal of Pain

Volumn 32, Issue 4, 2016, Pages 279-284

  Hwang, Catherine S ^a,b   Turner, Lydia W ^a,b   Kruszewski, Stefan P ^a,c,d   Kolodny, Andrew ^e,f,g   Caleb Alexander, G ^a,b,c,h  

^a Center for Drug Safety and Effectiveness   (United States)

^b Department of Epidemiology ^*  (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Stefan P Kruszewski and Associates   (United States)

^e BRANDEIS UNIVERSITY   (United States)

^f Phoenix House   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse; Chronic pain; Diversion; Opioid; Primary care; Survey

Indexed keywords

ILLICIT DRUG; OPIATE;

ADULT; ANALGESIA; ARTICLE; DOCTOR PATIENT RELATION; DRUG ABUSE; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH SURVEY; HUMAN; INTERNAL MEDICINE; INTERNIST; MAJOR CLINICAL STUDY; MALE; PAIN; PHARMACY; PHYSICIAN ATTITUDE; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION OPIOID ABUSE; PRIORITY JOURNAL; UNITED STATES; URINALYSIS; ATTITUDE TO HEALTH; DRUG MISUSE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PHYSICIAN; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PHYSICIANS; PHYSICIANS, PRIMARY CARE; PRESCRIPTION DRUG MISUSE; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84962570854     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0000000000000268     Document Type: Article

References (52)

1. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J Clin Psychiatry. 2011;72:589-592.
2. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012;43:283-289.
3. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR. 2011;60:1487-1492.
4. Centers for Disease Control and Prevention. Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR. 2010;59:705-709.
5. Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of non-malignant pain in the United States, 2000-2010. Med Care. 2013;51:870-878.
6. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980-2000. Pain. 2004;109:514-519.
7. Turk DC, Brody MC, Okifuji A. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain. 1994;59:201-208.
8. Weinstein SM, Laux LF, Thornby JI, et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J. 2000;93:479-487.
9. Ponte CD, Johnson-Tribino J. Attitudes and knowledge about pain: an assessment of West Virginia family physicians. Fam Med. 2005;37:477-480.
10. Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22: 1859-1865.
11. Nwokeji ED, Rascati KL, Brown CM, et al. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther. 2007;29(suppl):2589-2602.
12. Lin JJ, Alfandre D, Moore C. Physician attitudes toward opioid prescribing for patients with persistent noncancer pain. Clin J Pain. 2007;23:799-803.
13. Wilson HD, Dansie EJ, Kim MS, et al. Clinicians' Attitudes and Beliefs about Opioids Survey (CAOS): instrument development and results of a national physician survey. J Pain. 2013;14:613-627.
14. American Medical Association. AMA physician masterfile. 2014. Available at: http://www.ama-assn.org/ama/pub/about-ama/physician-data-resources/physician-masterfile.page. Accessed August 30, 2014.
15. Dillman DA. Mail and Telephone Surveys: the Total Design Method. New York, NY: John Wiley and Sons; 1978.
16. The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys, 7th ed. 2011. Available at: http://www.aapor.org/Standard-Definitions2.htm. Accessed August 30, 2014.
17. Lumley T. Analysis of complex survey samples. J Stat Softw. 2004;9:1-19.
18. Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA. 2012;307:1805-1806.
19. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP; 2011.
20. Hwang CS, Turner LW, Kruszewski SP, et al. Prescription drug abuse: results of a national survey of primary care physicians. JAMA Intern Med. 2015;175:302-304.
21. Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205-217.
22. Waters H. Abuse-resistant painkillers get mixed FDA response. Nat Med. 2011;17:905.
23. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. 2012. Available at: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20In stitute%20for%20Healthcare%20Informatics/IHII-Medicines- in-U.S-Report-2011.pdf. Accessed August 30, 2014.
24. Keating WR. Stop Tampering of Prescription Pills Act of 2013 (H.R. 486). 2013. Available at: http://beta.congress.gov/bill/113th-congress/house-bill/486. Accessed August 30, 2014.
25. Rogers H, Keating W, Wolf F, et al. Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs (H. Res. 161). 2013. Available at: http://www.gpo.gov/fdsys/pkg/BILLS-113hres161ih/pdf/BILLS-113hres 161ih.pdf. Accessed August 30, 2014.
26. Coburn T, Schumer C, McConnell M. Expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs (S. Res. 97). 2013. Available at: http://www.gpo.gov/fdsys/pkg/BILLS-113sres97is/pdf/BILLS-113sres97is.pdf. Accessed August 30, 2014.
27. Carter D, Srinivasan P. An act concerning health insurance coverage and abuse-deterrent prescription medications (H.B. 5484). 2013. Available at: http://www.cga.ct.gov/2013/TOB/h/pdf/2013HB-05484-R01-HB.pdf. Accessed August 30, 2014.
28. Barrar S, Baker M, Benninghoff K, et al. An act amending the act of September 27, 1961 (P.L.1700, No.699), entitled "An act relating to the regulation of the practice of pharmacy, including the sales, use and distribution of drugs and devices at retail; and amending, revising, consolidating and repealing certain laws relating thereto, " limiting substitution of certain opioid analgesic drugs by pharmacists (H.B. 1176). 2013. Available at: http://www.legis.state.pa.us/CFDOCS/Legis/PN/Public/btCheck.cfm?txtType = PDF&sessYr = 2013&sessInd = 0&billBody= H&billTyp= B&billNbr = 1176&pn =1472. Accessed August 30, 2014.
29. Substance Abuse and Mental Health Services Administration. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
30. Office of National Drug Control Policy, Executive Office of the President. Prescription for danger: a report on the troubling trend of prescription and over-the-counter drug abuse among the nation's teens. 2008. Available at: https://www.drugfreeactionalliance.org/files/downloadables/background-knowledge/B-Prescription-for-Danger.pdf. Accessed August 30, 2014.
31. Mezei L, Murinson BB. Pain education in North American medical schools. J Pain. 2011;12:1199-1208.
32. US Government Accountability Office. Prescription pain reliever abuse. 2011. Available at: http://www.gao.gov/assets/590/587301.pdf. Accessed March 15, 2015.
33. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:25.1-25.16.
34. National Institutes of Health Pain Consortium. Centers of Excellence in Pain Education (CoEPEs). 2014. Available at: http://painconsortium.nih.gov/NIH-Pain-Programs/CoEPES. html. Accessed March 15, 2015.
35. Executive Office of the President of the United States. National Drug Control Strategy. 2014. Available at: https://www. whitehouse.gov/sites/default/files/ndcs-2014.pdf. Accessed March 15, 2015.
36. Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). 2014. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrug-SafetyInformationforPatientsandProviders/UCM311290.pdf. Accessed March 15, 2015.
37. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342:1317-1322.
38. Pennsylvania Medical Society. Pennsylvania guidelines on the use of opioids to treat chronic noncancer pain. 2014. Available at: http://www.pamedsoc.org/DocumentVault/VaultPDFs/PatientcarePDFs/opioid-guidelines-PDF.html. Accessed October 10, 2014.
39. Franklin GM. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014;83:1277-1284.
40. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
41. Haddox JD, Joranson D, Angarola RT, et al. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13:6-8.
42. Federation of State Medical Boards of the United States. Model policy for the use of controlled substances for the treatment of pain. 2004. Available at: http://library.fsmb.org/pdf/2004-grpol-Controlled-Substances.pdf. Accessed August 30, 2014.
43. Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Annals Intern Med. 2010;152:712-720.
44. Adams NJ, Plane MB, Fleming MF, et al. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage. 2001;22:791-796.
45. Prescription Drug Monitoring Program Training and Technical Assistance Center. Status of state prescription drug monitoring programs. 2014. Available at: http://www.pdmpas sist.org/pdf/PDMPProgramStatus2014.pdf. Accessed March 15, 2015.
46. Prescription Drug Monitoring Program Center of Excellence. Mandating PDMP participation by medical providers: current status and experience in Kentucky. 2013. Available at: http://www.pdmpexcellence.org/sites/all/pdfs/COE%20briefing%20on% 20mandates%2011%2014%2013.pdf. Accessed March 15, 2015.
47. Tennessee Department of Health. Controlled Substance Monitoring Database and Prescription Safety Act. 2014. Available at: http://health.state.tn.us/boards/Controlledsub stance/faq.shtml. Accessed March 15, 2015.
48. Finklea K, Sacco LN, Bagalman E. Prescription drug monitoring programs. 2014. Available at: http://fas.org/sgp/crs/misc/R42593.pdf. Accessed March 15, 2015.
49. Rutkow L, Turner LW, Lucas E, et al. Most primary care physicians are aware of prescription drug monitoring programs, but many find data difficult to access. Health Aff. 2015;34:484-492.
50. Physicians Responsible for Opioid Prescribing (PROP). PROP petition to FDA. 2012. Available at: http://www.citizen.org/documents/2048.pdf. Accessed August 30, 2014.
51. Food and Drug Administration. FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics. 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm?source=govdelivery& utm-medium=email&utm-source=govdelivery. Accessed August 29, 2014.
52. Perrone J, DeRoos FJ, Nelson LS. Prescribing practices, knowledge, and use of prescription drug monitoring programs (PDMP) by a national sample of medical toxicologists, 2012. J Med Toxicol. 2012;8:341-352.